Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition (Tables)

v3.24.2.u1
Revenue Recognition (Tables)
 6 Months Ended
Jun. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue by Service Line
Revenue by Service Line
Three Months Ended June 30,
(in thousands) 2024 2023
Biologics and drug delivery
Disposable products $ 1,671  $ 346 
Services and license fees 2,656  3,022 
Subtotal – Biologics and drug delivery revenue 4,327  3,368 
Neurosurgery navigation and therapy
Disposable products 2,586  1,818 
Services —  383 
Subtotal – Neurosurgery navigation and therapy
 2,586  2,201 
Capital equipment and software
Systems and software products 687  173 
Services 258  208 
Subtotal – Capital equipment and software revenue 945  381 
Total revenue $ 7,858  $ 5,950 
Six Months Ended June 30,
(in thousands)
2024
2023
Biologics and drug delivery
Disposable products $ 2,224  $ 940 
Services and license fees 6,410  5,104 
Subtotal – Biologics and drug delivery revenue 8,634  6,044 
Neurosurgery navigation and therapy
Disposable products 4,513  3,676 
Services —  886 
Subtotal – Neurosurgery navigation and therapy
 4,513  4,562 
Capital equipment and software
Systems and software products 1,842  351 
Services 508  426 
Subtotal – Capital equipment and software revenue 2,350  777 
Total revenue $ 15,497  $ 11,383 
Schedule of Other Current Assets
June 30, 2024
December 31, 2023
(in thousands)
Accounts receivable, net $ 3,475  $ 3,211 
Other contract assets
Unbilled receivables $ 1,051  $ 733 
Schedule of Revenue Recognized by Contract Liability The unearned portion of all such fees is classified as deferred revenue.
June 30, 2024
December 31, 2023
(in thousands)
Deferred revenues $ 1,525  $ 3,154